Nano PharmaSolutions specializes in enhancing the bioavailability of poorly soluble drugs through innovative nanoformulation techniques. The company operates in the pharmaceutical and biotechnology sectors, focusing on rapid formulation development for first-in-human (FIH) studies. Nano PharmaSolutions serves pharmaceutical companies and research institutions looking to improve the efficacy of their drug candidates. The business model revolves around providing comprehensive, cost-effective solutions for drug formulation, which includes developing dry powder inhalation (DPI) formulations like remdesivir for early-stage COVID-19 treatment. Revenue is generated through partnerships and service contracts with pharmaceutical firms seeking to enhance their drug development processes.

Keywords: nanoformulation, bioavailability, insoluble drugs, pharmaceutical, biotechnology, drug development, FIH studies, DPI formulation, COVID-19, remdesivir.